Bevacizumab for long COVID breathing problems
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether a drug called bevacizumab can improve breathing and lung function in people who have long-lasting breathing problems after COVID-19. The drug works by reducing abnormal blood vessel growth that may contribute to lung damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You had COVID-19 confirmed by a test or CT scan more than 3 months ago.
- You still have shortness of breath that limits your daily activities (mMRC > 2).
- Your breathing test shows that your lung function is below 75% of the expected value.
- You are not currently pregnant, breastfeeding, or able to become pregnant.
- You have not had a heart attack, stroke, or major surgery in the last 3 months, and you do not have uncontrolled high blood pressure or serious kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a structured breathing control technique can improve symptoms of long COVID. It may help by training how you breathe, but you must meet specific health and medication criteria to join.
This trial studies how the lungs’ breathing (airflow) and blood flow may be off in people with long-COVID symptoms like tiredness, shortness of breath, or trouble exercising. It may help researchers understand what’s driving symptoms and what kinds of abnormalities could be targeted.
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
This trial tests whether a special dye attached to a cancer-targeting drug can help doctors see lung nodules more clearly during a bronchoscopy. This may make it easier to find and diagnose cancer during the procedure.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
This study looks at people with lingering post-COVID symptoms, especially breathing and lung-related findings, using home monitoring and medical tests. It may help researchers understand what’s driving ongoing symptoms and identify patterns that could guide better care.
Hear when a new Dyspnea Caused by 2019-nCoV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.